Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202

被引：0
|
作者：
Swiecicki, Paul
Yilmaz, Emrullah
Rosenberg, Ari J.
Fujisawa, Takao
Bruce, Justine Yang
Meng, Changting
Wozniak, Michele
Wang, Lu
Gorla, Seema Rao
Geiger, Jessica Lyn
机构：
[1] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL USA
[4] Natl Canc Ctr East Hosp, Dept Head & Neck Med Oncol, Translat Res Support Off, Chiba, Japan
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Seagen Inc, Bothell, WA USA
[7] Astellas Pharma US Inc, Northbrook, IL USA
[8] Astellas Pharma Inc, Northbrook, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6017
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202
    Swiecicki, P. L.
    Yilmaz, E.
    Rosenberg, A. J.
    Fujisawa, T.
    Bruce, J. Y.
    Meng, C.
    Wozniak, M. A.
    Wang, L.
    Gorla, S.
    Geiger, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E18 - E18
  • [2] Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202
    Muro, Kei
    Chin, Keisho
    Maron, Steven Brad
    Braiteh, Fadi S.
    Mitani, Seiichiro
    Hara, Hiroki
    Kuboki, Yasutoshi
    Mulcahy, Mary F.
    Baranda, Joaquina Celebre
    Gardner, Faithlore Patrice
    Jin, Ning
    Hamauchi, Satoshi
    Kaplan, Jason
    Gorla, Seema Rao
    Liu, Shubin
    Wozniak, Michele
    Meng, Changting
    Kondo, Shunsuke
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
    Bruce, Justine Yang
    Pusztai, Lajos
    Braiteh, Fadi S.
    Gorla, Seema Rao
    Wu, Chunzhang
    Baranda, Joaquina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer
    Muro, K.
    Bruce, J. Yang
    Baranda, J.
    Feinstein, T.
    Li, X.
    Gorla, S.
    Wu, C.
    Braiteh, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1096 - S1097
  • [5] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Honma, Yoshitaka
    Swiecicki, Paul L.
    Rosenberg, Ari Joseph
    Hanna, Glenn J.
    Yang Bruce, Justine
    Fujisawa, Takao
    Muro, Kei
    Kaplan, Jason B.
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS148 - TPS148
  • [6] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Swiecicki, Paul
    Rosenberg, Ari J.
    Hanna, Glenn J.
    Bruce, Justine Yang
    Fujisawa, Takao
    Honma, Yoshitaka
    Muro, Kei
    Kaplan, Jason
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
    Swiecicki, Paul L.
    Yilmaz, Emrullah
    Rosenberg, Ari Joseph
    Fujisawa, Takao
    Bruce, Justine Yang
    Meng, Changting
    Wozniak, Michele
    Zhao, Yongyun
    Mihm, Michael
    Kaplan, Jason
    Gorla, Seema
    Geiger, Jessica L.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05)
  • [8] Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer
    Ono, Makiko
    Bruce, Justine Yang
    Feinstein, Trevor
    Muro, Kei
    Derleth, Christina
    Gorla, Seema
    Wu, Chunzhang
    Novik, Yelena
    CANCER RESEARCH, 2022, 82 (04)
  • [9] EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts
    Muro, K.
    Bruce, J. Yang
    Baranda, J.
    Campbell, M.
    Wu, C.
    Gorla, S.
    Braiteh, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S298 - S298
  • [10] EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers
    Muro, K.
    Bruce, J.
    Baranda, J.
    Gorla, S.
    Wu, C.
    Braiteh, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S130 - S130
12345